NEW YORK (TheStreet) -- Shares of Roche Holding (RHHBY) are up 1.38% to $37.47 on heavy trading volume after CEO Severin Schwan told Reuters that the company's decision to buy U.S. biotech company InterMune (ITMN)  for $8.3 billion last month was "exceptional" and not a sign of more ambitious plans for major acquisitions.

Damping down expectations that Roche could embark on a series of such multibillion-dollar deals to bolster its presence in the treatment of rare diseases, Schwan said there was no change in the company's M&A strategy or its likely pace of deal-making, Reuters said.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

RHHBY data by YCharts

Image placeholder title

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.